Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"We Want To Shape Up Medical Treatment Paradigm Through Partnerships," Says Merck Asia-Pac President Ramesh Subrahmanian: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.

You may also be interested in...



MSD India Managing Director K.G. Ananthakrishnan On Disease Management And Taking A Holistic Approach: An Interview With PharmAsia News (Part 1 of 2)

Merck Sharp & Dohme India Managing Director K.G. Ananthakrishnan discusses MSD’s holistic approach to patient care in India, including disease management, physician education and responsible pricing.

Asia Spotlight: Innovative, Differentiated Generics To Lead Merck Into Emerging Markets, Says EM President Kevin Ali

MUMBAI – Merck & Co. President for Emerging Markets Kevin Ali likes to understand the “ground feel” of a company, says a senior company executive at its India affiliate MSD, and that need to see things in person may have brought the busy executive trotting back to India in less than three months of signing a “transformative deal” with Sun Pharmaceutical Industries Ltd.

Asia Spotlight: Innovative, Differentiated Generics To Lead Merck Into Emerging Markets, Says EM President Kevin Ali

MUMBAI – Merck & Co. President for Emerging Markets Kevin Ali likes to understand the “ground feel” of a company, says a senior company executive at its India affiliate MSD, and that need to see things in person may have brought the busy executive trotting back to India in less than three months of signing a “transformative deal” with Sun Pharmaceutical Industries Ltd.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel